<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>NeOnc Technologies Holdings, Inc. ( (NTHI) ) just unveiled an update. In the first quarter of 2026, NeOnc Technologies Holdings, Inc. reported completing the Phase 1 dose-escalation study of NEO212 and setting 610 mg as the recommended Phase 2 dose, with early signs of efficacy in heavily pretreated recurrent glioblastoma and brain metastasis patients. The company also fully enrolled its Phase 2a trial of NEO100 in recurrent IDH1-mutant high-grade glioma, citing previously reported remission and progression-free survival data ahead of an interim readout expected around August 2026. Operationally, NeOnc bolstered its balance sheet with a PIPE financing led by a $10 million commitment from Cinctive Capital and highlighted an undrawn $10 million credit line, expecting these resources to fund operations into September 2026. The company appointed David Choi as Chief Accounting Officer, reduced general and administrative expenses year over year, increased research and development spending to support its trials, and narrowed its quarterly net loss to $8.8 million compared with $32.3 million in the prior-year period. The most recent analyst rating on (NTHI) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on NeOnc Technologies Holdings, Inc. stock, see the NTHI Stock Forecast page. Spark’s Take on NTHI Stock According to Spark, TipRanks’ AI Analyst, NTHI is a Neutral. The score is primarily held down by very weak financial performance (no revenue, large losses, negative equity, and substantial cash burn implying ongoing financing needs). Technicals are mixed with a longer-term downtrend despite near-term stabilization. Offsetting these risks, corporate events are positive—capital raises extend runway and clinical/program milestones plus insider buying provide support—but they do not fully counterbalance the current financial strain. To see Spark’s full report on NTHI stock, click here. More about NeOnc Technologies Holdings, Inc. NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company focused on central nervous system cancers, developing therapeutics that address the challenges of the blood-brain barrier. Its NEO drug development platform has generated novel chemotherapy agents, including NEO100 and NEO212, both in Phase II trials for malignant gliomas and other CNS indications under FDA Fast-Track and IND status, supported by an exclusive worldwide patent portfolio licensed from the University of Southern California. The company’s portfolio targets oncological and neurological conditions with proprietary drug candidates and delivery methods protected by patents extending to 2038. Laboratory and clinical data have shown positive effects in various cancers, positioning NeOnc within the CNS oncology space as it advances multiple candidates toward potential commercialization. Average Trading Volume: 64,834 Technical Sentiment Signal: Strong Sell Current Market Cap: $139.1M See more data about NTHI stock on TipRanks’ Stock Analysis page.</div>

NTHI

NeOnc Technologies Holdings, Inc. reported progress in its glioma programs, completing a Phase 1 study of NEO212 and enrolling in a Phase 2a trial of NEO100. The company improved its financial position with a $10 million PIPE financing and reduced its quarterly net loss to $8.8 million. Analysts rate NTHI stock as a Buy with a $20.00 target, though concerns about financial performance persist. NeOnc focuses on CNS cancers, developing drugs under FDA Fast-Track status.

NeOnc Advances Glioma Programs and Strengthens Financial Position